

## A Review: Remdesivir and Covid-19

S M Devraye

Department of Chemistry

Late Ramesh WarpuDKar ACS College Sonpeth Dist. Parbhani (MS)

smdevraye@gmail.com

**Abstract:** *Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). It is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families. In this review, we have explained the structure of the coronavirus. Further it showed promising results in terms of clinical improvement, shortening the recovery time, mortality rate, and the duration of oxygen need and several studies showed positive results of Remdesivir against the new variants. Here, we provide an overview of Remdesivir, mode of action, and the current studies exploring its clinical effectiveness.*

**Keywords:** Remdesivir, COVID-19, Corona, Virus, Drug, Efficacy, SARS-CoV-2.

### REFERENCES

- [1]. Seyed Mohammad Reza Hashemian et.al. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19 Drug Design, Development and Therapy 2020;14 3215–3222.
- [2]. Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. *Travel Med Infect Dis.* 2020;35:101647. doi:10.1016/j.tmaid.2020.101647
- [3]. J. Grein, N. Ohmagari et.al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 *N Engl J Med* 2020;382:2327-36.DOI: 10.1056/NEJMoa2007016
- [4]. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed* 2020; 91: 157-60.
- [5]. Spinelli A, Pellino G. COVID-19 pandemic: perspectives on an unfolding crisis. *Br J Surg* 2020 March 19
- [6]. Muneerah M. Aleissa et.al. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 Antimicrobial Agents and Chemotherapy, January 2021 Volume 65 Issue 1 e01814-20
- [7]. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. 2020 *Ann Intern Med* <https://doi.org/10.7326/m20-5008>.
- [8]. Wang J, Du G. 2020. COVID-19 may transmit through aerosol. *Ir J Med Sci* 189:1143–1144. <https://doi.org/10.1007/s11845-020-02218-2>.
- [9]. Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. *Chembiochem.* 2020; 21(5):730– 738. doi:10.1002/cbic.202000047
- [10]. Fauci AS, Lane HC, Redfield RR. Covid-19 — navigating the uncharted. *N Engl J Med* 2020; 382: 1268-9.
- [11]. Mahase E, Kmiotowicz Z. Covid-19: doctors are told not to perform CPR on patients in cardiac arrest. *BMJ* 2020; 368: m1282.
- [12]. Rodriguez-Morales AJ, Cardona- Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. 2020 March 13 *Travel Med Infect Dis*
- [13]. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. *Lancet* 2020; 395: 1014-5.
- [14]. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. 2020 March 13 *JAMA Intern Med*
- [15]. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. 2020 March 23 *JAMA*
- [16]. Poston JT, Patel BK, Davis AM. Management of critically ill adults with COVID-19. 2020 March 26 *JAMA*
- [17]. Elfiky, A. A. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. *Journal of Biomolecular Structure and Dynamics*, 1–15. (2020). <https://doi.org/10.1080/07391102.2020.1761882>

- [18]. Mohamed A. Hendaus Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. 2021, Journal of Biomolecular Structure and Dynamics,39:10, 3787-3792, DOI: 10.1080/07391102.2020.1767691
- [19]. Boopathi, S., Poma, A. B., & Kolandaivel, P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. 2020.Journal of Biomolecular Structure and Dynamics, 1–14. <https://doi.org/10.1080/07391102.2020.1758788>
- [20]. Belouzard, S., Chu, V. C., & Whittaker, G. R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. 2009. Proceedings of the National Academy of Sciences of the United States of America, 106(14), 5871–5876. <https://doi.org/10.1073/pnas.0809524106>
- [21]. Hoffmann, M., Kleine-Weber, H., Krüger, N., Müller, M., Drosten, C., & Pöhlmann, S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. *BioRxiv*, 2020.1–23. <https://doi.org/10.1101/2020.01.31.929042>
- [22]. Wahedi, H. M., Ahmad, S., & Abbasi, S. W. (2020). Stilbene-based natural compounds as promising drug candidates against COVID-19. Journal of Biomolecular Structure and Dynamics, 2020. 1–16. <https://doi.org/10.1080/07391102.2020.1762743>
- [23]. Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science (New York, N.Y.)*2020, 367(6483), 1260–1263. <https://doi.org/10.1126/science.abb2507>
- [24]. Gupta, M. K., Vemula, S., Donde, R., Gouda, G., Behera, L., & Vadde, R. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. Journal of Bio-molecular Structure and Dynamics,2020. 1–11. <https://doi.org/10.1080/07391102.2020.1751300>
- [25]. Elfiky, A. A., & Azzam, E. B. Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective. Journal of Bio-molecular Structure and Dynamics, 2020.1–9. <https://doi.org/10.1080/07391102.2020.1758789>
- [26]. Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., Ray, A. S., Cihlar, T., Siegel, I. D., Mackman, R. L., Clarke, M. O., Baric, R. S., & Denison, M. R. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *Bio*, 2018. 9(2), 1–15. <https://doi.org/10.1128/mBio.00221-18>
- [27]. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature*. 2016;531(7594):381–385. doi:10.1038/nature17180
- [28]. Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a Pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. *J Med Chem*. 2017; 60(5):1648–1661. doi:10.1021/acs.jmedchem.6b01594
- [29]. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proc Natl Acad Sci U S A* 2020; 117: 6771-6.
- [30]. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* 2017; 9(396): eaal3653.
- [31]. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun* 2020; 11: 222.
- [32]. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020; 30: 269-71
- [33]. Ziyi Li et.al. Rapid review for the anti-coronavirus effect of remdesivir *Drug Discoveries & Therapeutics*. 2020; 14(2):73-76.
- [34]. Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. *J Infect Dis*. 2016; 213:1240-1247
- [35]. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. *N Engl J Med* 2019; 381: 2293-303.

- [36]. European Medicines Agency. Summary on compassionate use: Remdesivir Gilead. April 3, 2020 ([https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead\\_en.pdf](https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf)).
- [37]. World Health Organization.. WHO coronavirus Disease (COVID-19) dashboard. 2020. <https://covid19.who.int/>. Accessed 29 October 2020
- [38]. Vikas Bansal. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. *Frontiers in Medicine* 2 January 2021 | Volume 7 | Article 606429
- [39]. McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. *Open Forum Infect Dis*. 2020 7:ofaa105. doi: 10.1093/ofid/ofaa105
- [40]. FDA. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Remdesivir (GS-5734TM). 2020.
- [41]. Huda R. Taha et.al Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic” *Pharmacology* 2021;106:462–468
- [42]. Martin R, Li J, Parvangada A, Perry J, Cihlar T, Mo H, et al. Genetic conservation of SARSCoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. *Antiviral Res*. 2021; 188: 105033.
- [43]. Showers WM, Leach SM, Kechris K, Strong M. Analysis of SARS-CoV-2 mutations over time reveals increasing prevalence of variants in the spike protein and RNA-dependent RNA polymerase. *bioRxiv*. 2021 Mar 5. Epub ahead of print.
- [44]. Reuschl AK, Thorne L, Zuliani Alvarez L, Bouhaddou M, Obernier K, Soucheray M, et.al. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant. *bioRxiv*. 2021 Jan 24. Epub ahead of print.
- [45]. Lee J, Lee J, Kim HJ, Ko M, Jee Y, Kim S. TMPRSS2 and RNA-dependent RNA polymerase are effective targets of therapeutic intervention for treatment of COVID-19 caused by SARS-CoV-2 variants (B.1.1.7 and B.1.351). *bioRxiv*. 2021 Apr 8. Epub ahead of print
- [46]. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 2020;395(10236):1569-1578.
- [47]. Ohl ME, Miller DR, Lund BC, et al. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. *JAMA Network Open*.2021;4(7):e2114741
- [48]. Dyer O. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows. *BMJ*. 2020;371:m4057.
- [49]. Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. *BMJ Open*. 2021;11(6):e048416.
- [50]. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. *BMJ*. 2020;370:m2980.
- [51]. Yang C-J, Wei Y-J, Chang H-L, et al. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. *Journal of Microbiology, Immunology and Infection*. 2020;54(1):27-36.
- [52]. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. *N Engl J Med*. 2022;386(10):995-998.
- [53]. Bansal V, Mahapure KS, Bhurwal A, et al. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)*. 2020;7:606429.
- [54]. Alegre-Del Rey EJ, Gil-Sierra MD, Alarcon de la Lastra-Romero C, Sanchez-Hidalgo M. Remdesivir and mortality reduction in COVID-19 patients: a systematized subgroup analysis of clinical trials. *Farm Hosp*. 2021;45(1):28-31.
- [55]. Olender SA, Perez KK, Go AS, et al. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. *Clin Infect Dis*.2020.
- [56]. Erin K. McCreary. Efficacy of Remdesivir in COVID-19. *JAMA* September 15, 2020 Volume 324, Number 11
- [57]. Zeinab Mohseni Afshar et.al. Remdesivir: A critical review
- [58]. Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. *Clin Microbiol Rev* 2021. 34:e00162-20. <https://doi.org/10.1128/CMR.00162-20>.

- [59]. Andri Frediansyah, et al., Clinical Epidemiology and Global Health. <https://doi.org/10.1016/j.cegh.2020.07.011>
- [60]. Ashesha Mechineni, Hagar Kassab & Rajapriya Manickam. Remdesivir for treatment of COVID 19; review of the pharmacological properties, safety and clinical effectiveness, Expert Opinion on Drug Safety. 2021. DOI: 10.1080/14740338.2021.1962284
- [61]. Musa et al. Remdesivir for the Treatment of COVID-19. Western Journal of Emergency Medicine July 2020. Volume 21, no. 4
- [62]. Naser F. Al-Tannak et.a.; Review Remdesivir—Bringing Hope for COVID-19 Treatment. Sci. Pharm. 2020, 88, 29; doi:10.3390/scipharm88020029
- [63]. Russell, B., Moss, C., George, G., Santaolalla, A., Cope, A., Papa, S., Van Hemelrijck, M. Associations between immune-suppressive and stimulating drugs and novel COVID-19—A systematic review of current evidence. E cancer medical science 2020, 1410, 22.